**Abstract**

All the antipsychotic drugs currently available are acting on the postsynaptic dopamine receptors and the antipsychotic drugs may exert antipsychotic effect by blocking the receptor and reducing the elevated dopaminergic neurotransmission from presynaptic to postsynaptic area. However, all the antipsychotic drugs with the same mechanism of action are not all the same in the aspects of clinical efficacy. For example, clozapine shares its pharmacological characteristics with other antipsychotic drugs as a dopamine blocker. However, clozapine is the only antipsychotic drug with proven efficacy in refractory patients with schizophrenia. This could be associated with the unique pharmacological characteristics of clozapine that affects glutamatergic system, interacting with dopamine system in a co-modulatory manner. Furthermore, clozapine seems to affect functional connectivity between the frontal lobe and the striatum in a different manner influencing presynaptic dopamine synthesis.

In the present study, we sought to evaluate the antipsychotic effect on functional connectivity and presynaptic dopamine capacity and compare the effect between first-line antipsychotic drugs and clozapine.

For this, we measured functional connectivity by using resting MRI and presynaptic dopamine capacity by using \[18F\]DOPA PET in healthy volunteers (n=12) and patients with schizophrenia who were treated with first-line antipsychotic drugs (n=12) and clozapine (n=12), respectively.

Clozapine group showed lower ki values from \[18F\]DOPA than other groups and functional connectivity from resting MRI was negatively correlated with ki values. This might suggest that clozapine might make the functional connectivity stronger, leading to reduced presynaptic dopamine synthesis.
